Business
Bruker Announces Acquisition of MOLECUBES NV
Expands Nuclear Molecular Imaging Portfolio with Modular Benchtop CUBES™ PET, SPECT and CT Preclinical Imaging Systems GHENT, Belgium--(BUSINESS WIRE)--
About this update from Bruker Corporation
[{"type":"text","content":"\nExpands Nuclear Molecular Imaging Portfolio with Modular Benchtop CUBES™ PET, SPECT and CT Preclinical Imaging Systems\n\n GHENT, Belgium--(BUSINESS WIRE)--\nBruker Corporation (Nasdaq: BRKR) today announced the acquisition of MOLECUBES NV, a dynamic innovator in benchtop preclinical nuclear molecular imaging (NMI) systems. This acquisition strengthens Bruker’s position as a leading NMI solutions provider in preclinical and translational imaging research.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211119005258/en/Modular benchtop CUBES™ NMI systems of MOLECUBES (Photo: Business Wire)\nThe combination of Bruker’s preclinical imaging products and global footprint with the modular benchtop CUBES™ systems of MOLECUBES will provide a broader NMI offering to further accelerate worldwide adoption of preclinical NMI in academic medical centers and biopharma companies.\n\nDr. Wulf I. Jung, President of the Bruker BioSpin Preclinical Imaging Division commented: “Nuclear molecular preclinical and translational imaging research are growing market segments, in which we are already recognized for high-performance simultaneous PET/MR and PET/SPECT/CT instruments, and for our PMOD™ PET data analysis software. The acquisition of MOLECUBES adds scalable benchtop instruments to our portfolio for serving the NMI preclinical research community. The synergies between our and MOLECUBES’ research and development, applications and service teams is expected to benefit our combined NMI customers worldwide.”\n\nProfessor Roel Van Holen, CEO of MOLECUBES, added: “The MOLECUBES vision has always centered around making in vivo NMI available to every lab, by developing small footprint imagers without compromising on image quality. The high throughput of our unique scalable technology makes it an excellent tool to speed up drug discovery and translational research. Bruker has the reach to increase access to the CUBES in labs throughout the world, aligning with our joint mission to support the quality and speed of preclinical drug development and fundamental pathobiology research. Our team is looking forward to working within Bruker on research and innovative solutions for our existing and future customers.”\n\nAs a fast-growing company founded in 2015 in Ghent, Belgium, MOLECUBES develops and ...